Dafinchi AI

OPKO Health, Inc.

OPK

Healthcare

2w

Strategic Asset Sale and Focused Business Model for BioReference Health

OPKO is streamlining BioReference Health by preparing to sell its oncology and related clinical testing assets to Labcorp for $225 million, with $192.5 million payable at closing and an earn-out of up to $32.5 million based on performance.
The sale aims to monetize assets, sharpen focus on core testing operations, and improve financial profile.
Post-transaction, BioReference will retain core clinical testing in NY and NJ, including proprietary tests like 4Kscore, and expand into direct-to-consumer and employer-based testing.
Management emphasizes that this strategic move is expected to enhance margins and position BioReference for profitability.

CDNA

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA improved to $9.1 million from a loss of $0.3 million in Q2 2024.
Adjusted revenue for Q2 2025 was $90.5 million, up 14% year-over-year excluding prior period test revenue adjustments.
Cash from operations was $10 million, ending the quarter with $186 million in cash and no debt after a $50 million share repurchase.
Non-GAAP gross margin improved by 340 basis points to 70.4%, with Testing Services margin at 77.6%, Patient & Digital Solutions at 39.5%, and Lab Products at 63.9%.
Operating expenses increased 3% year-over-year to $56.7 million, well below revenue growth, reflecting operational leverage.
Patient & Digital Solutions revenue grew 19% to $12.8 million, and Lab Products revenue increased 12% to $11.8 million.
Reported revenue was $86.7 million, including a $3.8 million write-off related to prior period tests, down 6% year-over-year.
Testing Services revenue was $66 million adjusted, up 14% year-over-year with approximately 49,500 tests delivered, marking the eighth consecutive quarter of volume growth.

Vir Biotechnology, Inc.

VIR

Healthcare

1w

Financial Performance Summary

Cash, cash equivalents, and investments totaled approximately $892 million at quarter-end, providing runway into mid-2027.
Net cash consumed in Q2 2025 was approximately $127.7 million, including $50.5 million in milestone payments related to ECLIPSE 1 first patient dosed; excluding milestones, net cash consumed was about $77.2 million.
Net loss for Q2 2025 was $111 million, improved from a net loss of $138.4 million in Q2 2024.
R&D expenses for Q2 2025 were $97.5 million, down from $105.1 million in Q2 2024, driven by restructuring cost savings partially offset by clinical and oncology program expenses.
SG&A expenses for Q2 2025 were $22.3 million, down from $30.3 million in Q2 2024, due to headcount reductions and restructuring.
Total operating expenses for Q2 2025 were $119.6 million, a $42.1 million decrease from Q2 2024, reflecting lower R&D, SG&A, and absence of prior restructuring charges.

Myriad Genetics, Inc.

MYGN

Healthcare

1w

Myriad's Strategic Shift to Cancer Care Continuum Focus

Myriad is updating its long-range strategy to focus on the Cancer Care Continuum (CCC).
The new strategy aims to drive accelerated growth and profitability through three pillars: expanding in cancer diagnostics, growing prenatal and mental health markets, and maintaining financial discipline.
The company plans to leverage its leadership in hereditary cancer testing and expand into therapy selection, genomic profiling, immuno-oncology, and MRD testing.
Partnerships, such as with PATHOMIQ for AI-enabled prostate cancer testing, will play a key role in this expansion.
Management emphasizes increased urgency, disciplined execution, and strategic partnerships to achieve growth targets.

Definitive Healthcare Corp.

DH

Healthcare

1w

Financial Performance Summary

Adjusted EBITDA was $18.7 million, representing a 31% margin, also above guidance despite a year-over-year decline.
Adjusted gross profit was $50 million, down 6% year-over-year, with an 82% gross margin.
Adjusted net income was $9.7 million, or $0.07 per share, exceeding expectations.
Definitive Healthcare reported Q2 2025 revenue of $60.8 million, down 5% year-over-year but above the high end of guidance.
Subscription revenue declined 6%, partially offset by a 46% increase in professional services revenue.
The company generated $11.5 million in unlevered free cash flow in Q2 and $57 million on a trailing 12-month basis.
The company repurchased approximately 6 million shares for $19 million, with $58 million remaining under authorization.

Ginkgo Bioworks Holdings, Inc.

DNA

Healthcare

1w

Key Levers for Achieving 2026 EBITDA Targets

Ginkgo has successfully cut $250 million in costs over four quarters, with six more quarters to reach the 2026 target.
Future impact relies on further cost reductions, revenue growth from tools and automation, and managing underutilized lease space.
Management highlights the importance of automation, AI, and expanding tool offerings as primary drivers for reaching profitability.

Health Catalyst, Inc.

HCAT

Healthcare

1w

Financial Performance Summary

Adjusted operating expenses were $30.6 million, or 38% of revenue, improved from 40% in Q2 2024.
Adjusted professional services gross margin was 18%, down 190 basis points year-over-year but improved 250 basis points sequentially.
Adjusted technology gross margin was 66%, down 140 basis points year-over-year due to platform migration costs.
Adjusted total gross margin was 50%, slightly down 30 basis points year-over-year but up 30 basis points sequentially.
Cash and equivalents ended at $97 million, down from $392 million at year-end 2024, with term loan face value at $162 million after paying off $230 million convertible notes in April 2025.
Health Catalyst reported Q2 2025 revenue of $80.7 million, a 6% year-over-year increase, and adjusted EBITDA of $9.3 million, exceeding guidance and marking the highest adjusted EBITDA in company history.
Professional Services revenue declined 1% year-over-year to $27.8 million, impacted by contract restructuring and exits.
Technology segment revenue grew 11% year-over-year to $52.9 million, driven primarily by recurring revenue from new and acquired clients.

Bio-Rad Laboratories, Inc.

BIO

Healthcare

2w

Financial Performance Summary

Clinical Diagnostics sales were $389 million, flat reported and down 0.7% currency-neutral, impacted by lower diabetes testing reimbursement in China.
Core Life Science Group revenue excluding process chromatography decreased 1.7% reported and 2.7% currency-neutral due to softness in biotech and academic research markets.
Gross margin declined to 53% reported and 53.7% non-GAAP from 55.6% and 56.4% respectively in Q2 2024, due to higher material costs and lower instrument demand.
Life Sciences Group sales were $263 million, up 4.9% reported and 3.8% currency-neutral, driven by process chromatography and food safety products.
Net cash from operations was $117 million, free cash flow was $71 million, up from $98 million and $55 million respectively in Q2 2024.
Net sales for Q2 2025 were approximately $652 million, a 2.1% increase on a reported basis versus $638 million in Q2 2024, and a 1% increase on a currency-neutral basis.
Non-GAAP net income was $71 million or $2.61 per diluted share.
Operating income was $77 million (11.8% of sales) versus $101 million (15.9%) in Q2 2024; non-GAAP operating margin was 13.6% versus 16.7%.
Process chromatography experienced strong double-digit growth, with about 20% of Q2 sales pulled forward by customers.
R&D expenses were $61 million (9.3% of sales), slightly higher than prior year due to project-related spending.
Reported net income was $318 million or $11.67 per diluted share, boosted by a $250 million gain from Sartorius AG equity value changes.
SG&A expenses increased to $208 million (31.9% of sales) from $195 million (30.5%), driven by higher variable compensation.
Share repurchases totaled $139 million in Q2, with $337 million remaining under the current authorization.

McKesson Corporation

MCK

Healthcare

1w

Financial Performance Summary

Adjusted operating profit increased 9% to $1.4 billion, with three of four segments delivering double-digit growth in adjusted operating profit.
Corporate expenses decreased 4% excluding McKesson Ventures gains, driven by lower opioid-related expenses and technology costs.
First quarter earnings per diluted share increased 5% to $8.26, or 14% excluding gains from McKesson Ventures equity investments.
Free cash flow was negative $1.1 billion, impacted by $3.4 billion cash used for acquisitions and $189 million in capital expenditures.
International segment revenues increased 1% to $3.7 billion, with operating profit down 3% due to divestitures; excluding divested businesses, revenues grew 5% and operating profit was flat.
McKesson reported record consolidated revenues of $97.8 billion for Q1 fiscal 2026, a 23% increase year-over-year.
Medical-Surgical Solutions segment revenues increased 2% to $2.7 billion, with operating profit up 22% due to operational efficiencies and cost optimization.
Prescription Technology Solutions segment revenues increased 16% to $1.4 billion, with operating profit up 21%, driven by higher demand for access solutions including prior authorization services for GLP-1 medications.
U.S. Pharmaceutical segment revenues rose 25% to $90 billion, driven by increased prescription volumes, growth in oncology and specialty products, and new strategic customer onboarding.